Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oxymatrine and derivatives to prepare medicines treating skin vasculitis

A technology of skin vasculitis and derivatives, applied in the field of medicine, can solve problems such as limited adverse reactions and unsatisfactory treatment effects

Active Publication Date: 2016-02-10
施惠娟
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Due to the complex etiology of skin vasculitis, although there are many treatment methods, they all have their limitations and adverse reactions, and the treatment effect is not very satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Comparison of Acute Toxic Effects of Oxymatrine on Mice

[0024] Kunming mice were randomly divided into a normal control group and a test drug group, with ten mice in each group, half male and half male. In addition to the normal control group, the test drug group was injected intraperitoneally (ip) with a large dose of oxymatrine once, observed continuously for 7 days, and recorded the death time and number of animals.

[0025] The results showed that when the dose of oxymatrine was 950mg / kg, it had great toxicity, and 9 out of 10 mice died.

[0026] Comparison of acute toxic effects of epioxymatrine, glycyrrhizic acid and their combination (ip once) on mice

[0027] group Dose (mg / kg) Deaths / Total normal control group 0 0 / 10 bitter 950 9 / 10

[0028] Remarks: "Bitter": means oxymatrine.

Embodiment 2

[0030] Clinical Observation on Treating Pigmented Purpuric Dermatitis with Oxymatrine

[0031] 1 Materials and methods

[0032]1.1 Clinical data Clinical diagnosis of 7 patients with pigmented purpura-like dermatitis, 4 males and 3 females, aged 24 to 60 years old, had not received systemic treatment within one month, no photosensitivity disease, no liver and kidney dysfunction, etc. Severe visceral diseases, no history of active tuberculosis, cataract, pregnant and lactating women were excluded.

[0033] 1.2 Treatment method Intravenous infusion of oxymatrine injection 0.6g100ml / d; 8 weeks as a course of treatment, after the course of treatment is over, the curative effect will be judged.

[0034] 1.3 Criteria for judging the curative effect: clinical recovery means that the skin lesions have disappeared after treatment by more than 90%; markedly effective means that the skin lesions have disappeared by 60% to 89%; progress means that the skin lesions have disappeared by 2...

Embodiment 3

[0041] Clinical Observation of Oxymatrine in Treating Allergic Cutaneous Vasculitis

[0042] 1 Materials and methods

[0043] 1.1 Clinical data The clinical diagnosis is consistent with allergic cutaneous vasculitis in 3 patients, 2 males and 1 female, aged 24-33 years, who have not received systemic treatment within one month, no photosensitivity disease, no liver and kidney dysfunction Severe visceral diseases, no history of active tuberculosis, cataract, pregnant and lactating women were excluded.

[0044] 1.2 Treatment method Intravenous infusion of oxymatrine injection 0.6g100ml / d; all 6 weeks as a course of treatment, after the course of treatment is over, the curative effect will be judged.

[0045] 1.3 Criteria for judging the curative effect: clinical recovery means that the skin lesions have disappeared after treatment by more than 90%; markedly effective means that the skin lesions have disappeared by 60% to 89%; progress means that the skin lesions have disappea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of pharmaceutically-acceptable forms and derivatives of oxymatrines(oxymatrine, matrine and iosmatrine) to prepare medicines treating skin vasculitis (such as allergic cutaneous vasculitis, allergic purpura, erythema elevatum diutinum, acute febrile neutrophilic dermatosis, urticarial vasculitis, pustular vasculitis, polyarteritis nodosa, gnagrenous pyoderma, eosinophilic vasculitis, eosinophilic cellulitis, pigmented purpuric dermatoses, wegner granulomatosis, behcet disease, erythema nodosum, and erythema induratum).

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the application of a medicine for preventing and treating skin vasculitis. The medicine is matrine (oxymatrine, matrine, isomatrine) or a pharmaceutically acceptable form or derivative thereof and a medicine box containing the medicine. Background technique [0002] Vasculitis is a clinicopathological process manifested by inflammation and necrosis of blood vessels and their surroundings. Histopathological changes can present a series of changes ranging from simple mild necrotizing vasculitis to granulomatous changes. Infiltrating cells can be neutrophils, lymphocytes, eosinophils, and histiocytes. Due to the different locations, sizes, scopes, degrees, and inflammatory and necrotic reactions of the involved blood vessels, various clinical manifestations are presented. The etiology of cutaneous vasculitis is not fully understood. Possible causes include: 1. Infection: such as chronic to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P9/00A61P17/00A61P7/04A61P9/14
Inventor 施惠娟
Owner 施惠娟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com